We are very grateful to the supporters of the 33rd International Symposium on ALS/MND, held virtually on 6-9 December 2022:
Cytokinetics is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for diseases in which muscle performance is compromised, including heart failure, HCM and ALS. As a leader in muscle biology, Cytokinetics is developing small molecule drug candidates engineered to impact muscle function and contractility.
Amylyx is a biopharmaceutical company with the mission to develop therapies for neurodegenerative diseases. With offices in Cambridge, Massachusetts; Canada; and Amsterdam, NL, Amylyx collaborates with people living with neurodegenerative diseases and their caregivers, industry leaders, scientists, doctors, and research organizations to make a positive impact. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative disease.
BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics, Inc. is a clinical-stage, biotechnology company focused on the development of best-in-class autologous cellular therapeutics for the treatment of highly debilitating neurodegenerative diseases. BrainStorm has completed a Phase 3 clinical trial in ALS, and a Phase 2 clinical trial in progressive MS.
At Ferrer we want to make a positive impact in society and we do so by reinvesting a significant part of our profits in initiatives with social and environmental impact, as well as in our people. In order to fulfil our purpose, we offer transformative therapeutic solutions, with an increasing focus on pulmonary vascular and interstitial lung diseases and neurological disorders, such as ALS.
We are Ferrer, Ferrer for good.
LifeArc helps translate science into medical breakthroughs for patients. We are driven to bridge the gap between the lab and the patient, by working with some of the world’s leading thought leaders, life science organisations, scientists, charities, and medical institutions, to accelerate discoveries into next generation diagnostics, treatments and cures for people who need it most. In 2021, LifeArc committed to investing and partnering in novel research for six unmet health needs starting with the areas of Chronic Respiratory Infection, Neurodegeneration and Global Health Infection. Drawing on almost three decades of experience, we will invest £1.3bn to deliver new treatments and health solutions for these and other underfunded and under supported areas by 2030.
Apellis Pharmaceuticals, Inc., is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in Complement, at the forefront of targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement.
Mitsubishi Tanabe Pharma America
Mitsubishi Tanabe Pharma America, Inc. (MTPA) is relentlessly focused on the goal of providing therapies for some of the most difficult-to-treat diseases. Our teams work diligently to develop smart options that will enable healthcare providers to offer safe and effective treatments for devastating illnesses. We thrive on solving complex problems in science and medicine and strive to make a real difference in the lives of people struggling with debilitating diseases.
QurAlis is trailblazing the path to conquering amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets with next-generation precision medicines. QurAlis’ proprietary platforms and unique biomarkers enable the design and development of drugs that act directly on disease-causing genetic alterations. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a deep pipeline of antisense oligonucleotides and small molecule programs including addressing sub-forms of ALS that account for the majority of ALS patients.
Zambon Biotech is a new international innovation hub part of Zambon, a modern healthcare company founded in 1906 on the history and values of an Italian family. Our mission is to create a long-term pipeline aligned with Zambon deep purpose to make patients’ lives better. Thanks to a license agreement signed in 2019 with Aquestive Therapeutics Inc., the Zambon Biotech team, based in Switzerland, is working towards the development and commercialization of a new product for patients with amyotrophic lateral sclerosis (ALS).